Tissue plasminogen activator, recombinant

Fig. 2. Outline of possible steps in the recovery and purification sequence for recombinant tissue plasminogen activator derived from recombinant CHO...

Fig. 4. Fibrinolytic system where SCUPA is single-chain urokinase plasminogen activator rTPA is recombinant tissue plasminogen activator APSAC is acylated plasminogen streptokinase activator complex SK is streptokinase and UK is urokinase.

Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R, Boy sen G, Bluhmki E, Hoxter G, Mahagne MH. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA 1995 274 1017-1025. [Pg.34]

Stroke is the leading cause of major long-term disability in adults and the third leading cause of death in the United States. On average, a new stroke occurs every 45 seconds. Thrombolytic therapy with intravenous recombinant tissue-plasminogen activator (IV rt-PA) is the most effective treatment for acute ischemic stroke. In this chapter, we review the rationale for thrombolysis in acute ischemic stroke, clinical evidence supporting the use of thrombolytics, and the application of thrombolysis in practice. [Pg.39]

Del Zoppo GJ, Poeck K, Pessin MS, Wolpert SM, Eurlan AJ, Ferhert A, Alberts MJ, Zivin JA, Wechsler L, Busse O. Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke. Ann Neurol. 1992 32 78-86. [Pg.55]

Kwiatkowski TG, Libman RB, Frankel M, Tilley BC, Morgenstem LB, Lu M, Broderick JP, Lewandowski CA, Marler JR, Levine SR, Brott T. Effects of tissue plasminogen activator for acute ischemic stroke at one year. National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study Group. New England Journal of Medicine. 1999 340 1781-1787. [Pg.56]

Larrue V, von Kummer RR, Muller A, Bluhmki E. Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator A secondary analysis of the european-australasian acute stroke study (ECASS II). Stroke. 2001 32 438 1. [Pg.57]

Tanne D, Kasner SE, Demchuk AM, Koren-Morag N, Hanson S, Grond M, Levine SR. Markers of increased risk of intracerebral hemorrhage after intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke in clinical practice The Multicenter rt-PA Stroke Survey. Circulation. 2002 105 1679-1685. [Pg.58]

Kent DM, Price LL, Ringleb P, Hill MD, Selker HP. Sex-based differences in response to recombinant tissue plasminogen activator in acute ischemic stroke A pooled analysis of randomized clinical trials. Stroke. 2005 36 62-65. [Pg.58]

Kleindorfer D, Kissela B, Schneider A, Woo D, Khoury J, Miller R, Alwell K, Gebel J, Szaflarski J, Pancioli A, Jauch E, Moomaw C, Shukla R, Broderick JP. Eligibility for recombinant tissue plasminogen activator in acute ischemic stroke a population-based study. Stroke. 2004 35 e27-29. [Pg.61]

Wiese KM, Talkad A, Mathews M, Wang D. Intravenous recombinant tissue plasminogen activator in a pregnant woman with cardioembolic stroke. Stroke. 2006 37 2168-2169. [Pg.61]

Thirumalai SS, Shubin RA. Successful treatment for stroke in a child using recombinant tissue plasminogen activator. J Child Neurol. 2000 15 558. [Pg.62]

Wolpert SM, Bmckmann H, Greenlee R, Wechsler L, Pessin MS, del Zoppo GJ. Neuror-adiologic evaluation of patients with acute stroke treated with recombinant tissue plasminogen activator. The rt-PA Acute Stroke Smdy Group. Am J Neuroradiol 1993 14 3-13. [Pg.91]

Ernst R, Pancioli A, Tomsick T, Kissela B, Woo D, Kanter D, Jauch E, Carrozzella J, Spilker J, Broderick J. Combined intravenous and intra-arterial recombinant tissue plasminogen activator in acute ischemic stroke. Stroke 2000 31 2552-2557. [Pg.92]

Zeumer H, Ereitag HJ, Zanella E, Thie A, Arning C. Local intra-arterial fibrinolytic therapy in patients with stroke urokinase versus recombinant tissue plasminogen activator (r-TPA). Neuroradiology 1993 35 159-162. [Pg.94]

Straub S, Junghans U, Jovanovic V, Wittsack HJ, Seitz RJ, Siebler M. Systemic thrombolysis with recombinant tissue plasminogen activator and tirofiban in acute middle cerebral artery occlusion. Stroke 2004 35 705-709. [Pg.158]

The severity of the neurological deficit at the time of stroke onset is a major predictor of stroke outcome. In an analysis of the placebo-treated patients in the National Institute of Neurological Disorders and Stroke (NINDS) recombinant tissue-plasminogen activator (rt-PA) study, the best acute predictor of a poor outcome at 1 year was an National Institute of Health Stroke Scale (NIHSS) score >17 for patients over 70 years. These criteria had a high specificity (98%), but sensitivity was only 31%. The low sensitivity of the acute NIHSS score alone in predicting... [Pg.198]

Yim, K. W., Fractionation of the human recombinant tissue plasminogen activator (rtPA) glycoforms by high-performance capillary zone electrophoresis and capillary isoelectric focusing, /. Chromatogr , 559, 401, 1991. [Pg.425]

The first large-scale process to circumvent these limitations was one developed by Genentech, Inc. (South San Francisco, CA) for production of recombinant tissue plasminogen activator (tPA). This protein dissolves blood clots and can be used to treat heart attacks and strokes. This process was developed in the mid-1980s, resulting in final product licensure in 1987. The process required both regulatory and technical breakthroughs. [Pg.104]

Al-Buhairi, A. and Jan, M. 2002. Recombinant tissue plasminogen activator for acute ischemic stroke. Saudi Medical Journal 23(1), 13-19. [Pg.368]

Keratan sulfate (102-104), hen ovomucin (105), rat gastric mucins (106), porcine thyroglobulin (107) Recombinant tissue plasminogen activator expressed in mouse epithelial cells (108)... [Pg.329]

M. V. Paranandi, A. W. Guzzetta, W. S. Hancock, D. W. Aswad, Deamidation and Isoaspartate Formation During in vitro Aging of Recombinant Tissue Plasminogen Activator , J. Biol. Chem. 1994, 269, 243-253. [Pg.375]

Tenecteplase (TNKase) [Thrombolytic/Recombinant Tissue Plasminogen Activator] Uses Restore perfusion i mortality w/ AMI Action Thrombolytic TPA Dose 30-50 mg see Table III-l Caution [C, ], T Bleeding w/ NSAIDs, ticlopidine, clopidogrel, GPIIb/IIIa antagonists Contra Bleeding, CVA, major surgery (intracranial, intraspinal) or trauma w/in... [Pg.296]

ReFacto (Moroctocog-a, i.e. Genetics Institute B-domain-deleted rhFactor VIII produced in CHO cells) Recombinant tissue plasminogen activator-based products Haemophilia A 1999 (EU), 2000 (USA)... [Pg.500]

Also known as recombinant tissue Plasminogen Activator (rt-PA). It is produced by recombinant DNA technology from human tissue culture. It specifically activates plasminogen bound to the fibrin clot. This minimises the risk of systemic bleeding. [Pg.246]

Tenecteplase, human recombinant tissue plasminogen activator (tPA) produced in CHO cells... [Pg.453]

Tenecteplase, human recombinant tissue plasminogen activator... [Pg.524]

Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...